Printer Friendly

Health Discovery Corporation Applies for U.S. and Foreign Patent Protection of Prostate Disease Biomarkers Identified Using SVM Technology.

SAVANNAH, Ga. -- Health Discovery Corporation ("HDC") announced today that it has filed patent applications in the United States Patent and Trademark Office and in the U.S. Receiving Office for the Patent Cooperation Treaty for U.S. and foreign patent protection of biomarkers for diagnosis, treatment and monitoring of prostate disease. The patent claims cover multiple genetic sequences that were identified using HDC's patented support vector machine (SVM)-based technology as having the greatest significance for reliably distinguishing among different types of prostate disease as well as for separating diseased prostate from normal tissue.

"These biomarker discoveries by our world-renowned science team present a great opportunity within the vexing field of prostate cancer," said Stephen D. Barnhill, M.D., Chairman & CEO of Health Discovery Corporation. "I firmly believe that these discoveries offer a significant step towards more accurate diagnosis and more defined therapeutic targets in this primary battlefield of cancer. HDC's science team is eager to work with both diagnostic and pharmaceutical partners on developing prospective commercial applications from these important discoveries."

Among the new sets of biomarkers are genes that provide a high degree of accuracy for distinguishing BPH (Benign Prostatic Hyperplasia) from prostate cancer and from all other tissue, including normal tissue. BPH is the enlargement of the prostate gland that occurs as men age, affecting over 33 million men worldwide. The identification of specific genetic markers that clearly separate BPH samples from normal tissue confirms that BPH is a disease with its own unique molecular characteristics. This discovery can be used to develop a non-invasive diagnostic test for BPH, which does not currently exist, as well as tools for developing new types of therapy for patients with this disease.

HDC has identified additional sets of biomarkers that are capable of distinguishing high-grade prostate cancers (Gleason Grade 4 and higher) from less malignant grades. Other marker gene sets were identified for clearly separating cancer from normal and cancer from BPH. More than 1 million men a year undergo biopsies of the prostate gland after the widely used cancer-screening test reveals moderately elevated levels of prostate specific antigen (PSA) in the blood. Only one in four of these biopsies finds evidence of cancer, meaning that around 750,000 of those million plus biopsies were unnecessary. The ability to clearly distinguish between different cancer grades by measuring the levels of the marker genes in tissue, blood, or possibly even semen, would reduce the number of unneeded biopsies while quickly identifying those men in urgent need of more aggressive treatment.

The new biomarkers pave the way for possible non- and minimally-invasive tests for screening, diagnosis and monitoring of prostate disease with greater accuracy and reliability than is currently available with the widely used PSA test. The ability to readily distinguish between the different conditions allows physicians to tailor prostate treatment for each patient, including whether cancer is present and, if so, type or grade of cancer. Such capabilities will yield significant cost savings by minimizing the need for biopsies and unnecessary or overly aggressive treatments as well as eliminating the adverse effects that invariably accompany unnecessary treatments. The biomarkers also serve as starting points for development of new treatments for prostate disease.

Savannah-based Health Discovery Corporation (OTCBB:HDVY) is uniquely positioned in the field of pattern recognition. Through its broad patent portfolio and the efforts of its recognized scientific team, HDC is focused on commercializing its intellectual property in genomic and proteomic biomarker discovery, medical imaging, diagnostics, and pharmaceutical advancements in personalized medicine. The company's patent-protected technology also has significant application in non-medical fields that require manipulation and analysis of large, complex datasets such as insurance, financial markets, Internet search & spam, and homeland security.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Health Discovery Corporation Applies for U.S. and Foreign Patent Protection of Prostate Disease Biomarkers Identified Using SVM Technology.
Publication:Business Wire
Geographic Code:1USA
Date:Nov 30, 2005
Previous Article:Knock-Out Technologies, Ltd. Receives First Purchase Order for Sale of Citroxin Cleaner; Citroxin, a shared technology with Big Six Plus Germicidal,...
Next Article:HomePlug(R) Powerline Alliance Receives Unprecedented Response at Premier Japan Executive Seminar; Highlight of Ongoing Alliance World Tour.

Related Articles
Applying Biomarker Research.
Application of biomarkers to environmental health and risk assessment.
Health Discovery Corporation Announces Approval and Issuance of Multiple Patent Applications Covering SVM Methods.
Health Discovery Corporation Announces New Patent Issuance; Issued Patent Covers Support Vector Machine Pre-Processing Methods.
Health Discovery Corporation Announces Significant Expansion of Its Intellectual Property Portfolio; Company Issued Additional Patents Covering Its...
Health Discovery Corporation Announces Issuance of New U.S. Patent Covering SVM-Based Image Analysis Including Digital Mammography.
Health Discovery Corporation Receives Pioneering U.S. Patent for Its Renowned RFE-SVM Technology.
Health Discovery Corporation Obtains Consent Judgment in Patent Lawsuit against Equbits LLC.
Health Discovery Corporation Files for U.S. and Foreign Patent Protection of New Prostate Cancer Biomarker Discovery.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters